Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Abstract Text:

Peter Martin,Richard R Furman,Morton Coleman,John P Leonard,Peter Martin,Richard R Furman,Morton Coleman,John P Leonard,

Led by the anti-CD20 antibody rituximab, therapeutic monoclonal antibodies have dramatically altered the treatment of patients with non-Hodgkin's lymphoma. As the understanding of the biology of this novel therapy improves, so does the potential for further progress. There are currently four monoclonal antibodies approved by the Food and Drug Administration for the treatment of B-cell malignancies and dozens more are in various stages of development. The indications for the currently available antibodies, both labeled and unlabeled, are being expanded to include first-line treatment, maintenance strategies, and combinations with chemotherapy. Newer agents are being engineered to target novel antigens, and to interact more specifically with the host immune system. These promising therapeutics face a significant challenge in evaluation and integration in the post-rituximab world.

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Publishing Authors By Initials

P Martin,RR Furman,M Coleman,JP Leonard,P Martin,RR Furman,M Coleman,JP Leonard,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Journal Published:

PUBLICATION TYPE: Review

Journal: Clinical cancer research : an official journal of

VOLUME: 13

Page Numbers: 5636s-5642s

Journal Abbreviation: Clin. Cancer Res.

ISSN: 1078-0432

DAY: 15

MONTH: Sep

YEAR: 2007

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Information

Number of References: 77

LANGUAGE: eng

NlmUniqueID: 9502500

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.

AFFILIATION: Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, and New York Presbyterian Hospital, New York, New York 10021, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma Related Publications

• Alcohol use and partner expectations among newly married couples.
• Alterations in proximal femur geometry in children treated with glucocorticoids for Crohn disease or nephrotic syndrome: impact of the underlying disease.
• Clinical markers for specific language impairment in Italian: The contribution of clitics and non-word repetition.
• Development of a video-based evaluation tool in Rett syndrome.
• Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression.
• Effects of acoustic manipulation on the real-time inflectional processing of children with specific language impairment.
• Finite verb morphology and phonological length in the speech of children with specific language impairment.
• Gender differences in body composition deficits at diagnosis in children and adolescents with Crohn's disease.
• HPA and immune axes in stress: involvement of the serotonergic system.
• Inflammation, depression and dementia: are they connected?
• Integrative behavioral couple therapy for chronic pain: promoting behavior change and emotional acceptance.
• Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures.
• Nanoparticles of hydrophobically modified dextrans as potential drug carrier systems.
• Neonatal bladder rupture: A rare etiology.
• Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.
• Predictors of scoliosis in Rett syndrome.
• Predictors of seizure onset in Rett syndrome.
• Processing limitations and the grammatical profile of children with specific language impairment.
• Quantitative microcomputed tomography assessment of intratrabecular, intertrabecular, and cortical bone architecture in a rat model of severe renal osteodystrophy.
• Renal function measurements from MR renography and a simplified multicompartmental model.
• Risk factors for mortality among adult patients with newly diagnosed tuberculosis in Samara, Russia.
• Seizures in Rett syndrome: an overview from a one-year calendar study.
• The adoption of distance education technology in a master of health administration (MHA/MHSc) curriculum: anecdotes and antidotes.
• The development of aggression in 18 to 48 month old children of alcoholic parents.
• The drinking partnership and marital satisfaction: The longitudinal influence of discrepant drinking.
• The effect of temporal adverbials on past tense production by children with specific language impairment.
• The molecular basis of IL-21-mediated proliferation.
• The overgeneralization of non-finite complements to finite contexts: the case of decide.
• The production of finite and nonfinite complement clauses by children with specific language impairment and their typically developing peers.
• Women's physical aggression in bars: an event-based examination of precipitants and predictors of severity.